Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 4, 2026

S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results

View original at finance.yahoo.com
S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results NEW YORK, June 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") conducted a consultation with market participants on potential changes to the S&P U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No changes will be made to the eligibility criteria including financial viability screens, seasoning period, or minimum IWF for the S&P 500, S&P MidCap 400, or S&P SmallCap 600 as a result of the consultation on the treatment of MegaCap companies.

    60% confidence
  • The decision not to adopt the proposed exceptions preserves core index principles by maintaining consistent application of key eligibility requirements.

    60% confidence
  • The Index Committee is not bound by any comments or information submitted as part of the consultation.

    60% confidence
  • Market consultations are the primary mechanism through which the Index Committee engages with market participants to seek feedback on whether methodology changes are necessary or appropriate.

    60% confidence
  • The S&P indices can continue to meet their stated objectives while preserving their role as representative and investable benchmarks for the U.S. equity market under the existing methodology.

    60% confidence
  • Exceptions to the financial viability, seasoning, and IWF requirements should not be granted solely based on market capitalization.

    60% confidence
  • Although there may be trade-offs between strict adherence to eligibility requirements and broad representativeness, the current methodology provides substantial market coverage and sector balance.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results — Source | Via News | Via News